Trials / Unknown
UnknownNCT02919371
Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)
Phase I/II Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)
- Status
- Unknown
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 77 (estimated)
- Sponsor
- King Faisal Specialist Hospital & Research Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
Combined sunitinib and bevacizumab in advanced renal cell carcinoma.
Detailed description
This is a phase I/II trial of combined sunitinib and bevacizumab in advanced renal cell carcinoma ( CASBA) where Bevacizumab will be used only on day 29 of each 6 weeks sunitinib cycle.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sunitinib | Oral therapy ( Anti-vascular endothelial growth factor Tyrosin Kinase Inhibitor): given as 50 mg daily from day 1 to day 28- cycle repeated every 42 days |
| DRUG | Bevacizumab | Monoclonal antibody against vascular endothelial growth factor: given intravenously on day 29 of each sunitinib cycle |
Timeline
- Start date
- 2014-12-01
- Primary completion
- 2020-12-01
- Completion
- 2021-12-01
- First posted
- 2016-09-29
- Last updated
- 2018-08-10
Locations
1 site across 1 country: Saudi Arabia
Source: ClinicalTrials.gov record NCT02919371. Inclusion in this directory is not an endorsement.